rheumatology
Gout

Combo therapy kicks urate target goals


The use of combined xanthine oxidase inhibitors (febuxostat) with a uricosuric agent (lesinurad) has shown long term safety and efficacy in patients with tophaceous gout in a trial involving Australian centres. In a two year follow up study, febuxostat and lesinurad were effective in lowering serum urate levels, reducing gout flares and decreasing the size ...

Already a member?

Enter your email to keep reading.


OR